Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 8:00 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 8:00 AM ET. The event will include virtual one-on-one meetings for registered investors. A live webcast will be available on the company’s website, with a replay accessible two hours post-event for 90 days. Corbus focuses on innovative immunology solutions targeting the immune system and cancer.
Details
News Market Reaction – CRBP
The recorded move for CRBP in the trading session of this news was +5.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORWOOD, Mass., March 11, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022 at 8:00 AM ET.
In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the fireside chat will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com. The webcast replay will be available approximately two hours after the event and will be archived for 90 days.
About Corbus
Corbus is an immunology company committed to connecting innovation to our purpose of improving lives by developing new medicines that target the nexus between the immune system and cancer. Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
INVESTOR CONTACT:
Brian Walsh, VP, Corporate Development
Email: brian.walsh@corbuspharma.com
Phone: +1 (781) 264 8944
View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-301500516.html
SOURCE Corbus Pharmaceuticals
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.